In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Our recent trials combining local radiotherapy with intratumoral administration of TLR
agonists - referred to as 'in situ vaccination' - for patients with low-grade lymphoma
demonstrated safety, induction of anti-tumor CD8 T cell responses and partial and complete
remissions of patients' non-irradiated sites of disease with complete remissions lasting from
months to more than three years.
This iteration of the in situ vaccine approach builds on our prior work in ways that should
improve its efficacy, by adding Flt3L and changing the toll-like receptors (TLR) agonist to
poly-ICLC -an optimal TLR agonist for the type of dendritic cells (DC) recruited by Flt3L.
The vaccine is thus in 3 phases:
1. intratumoral Flt3L administration recruits DC to the tumor
2. low-dose radiotherapy to release tumor antigens
3. intratumoral poly-ICLC administration activates tumor-antigen loaded DC
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Joshua Brody
Collaborator:
Celldex Therapeutics
Treatments:
Carboxymethylcellulose Sodium Flt3 ligand protein Poly I-C Poly ICLC